NCT04965870View on ClinicalTrials.gov

A Study of Trifluridine/ Tipiracil in Chemorefractory mCRC in Greece

CompletedOBSERVATIONAL
Enrollment

200

Participants

Timeline

Start Date

June 30, 2021

Primary Completion Date

October 31, 2021

Study Completion Date

December 20, 2021

Conditions
Metastatic Colorectal Cancer
Interventions
DRUG

Trifluridine/Tipiracil

Trifluridine/ Tipiracil is an oral combination of an antineoplastic thymidine-based nucleoside analogue, trifluridine, and the thymidine phosphorylase (TPase) inhibitor, tipiracil hydrochloride.

Trial Locations (8)

11525

Athens Medical Group, Athens

14564

"General Oncological Hospital Agioi Anargyroi", Athens

18537

"Anticancer Hospital METAXA", Piraeus

70013

University General Hospital of Heraklion (PAGNI), Heraklion

71409

"General Hospital Venizeleio - Pananio", Heraklion

Unknown

Agios Savvas Cancer Hospital, Athens

Attikon University Hospital, Athens

Bioclinic, Thessaloniki

All Listed Sponsors
collaborator

Servier

INDUSTRY

lead

Hellenic Study Group of Psychoneuroimmunology in Cancer

NETWORK